Hsin-Jung Wu has extensive experience in the field of pharmacology, with a focus on in vivo studies and anti-tumor immunity. Hsin-Jung has held roles as a Principal Scientist at Tango Therapeutics, a Sr. Scientist II at Blueprint Medicines, and a Sr. Scientist at Foghorn Therapeutics, Inc. In these positions, they have led in vivo studies, managed outsourced projects, and built internal capabilities. Hsin-Jung has also worked as a Scientist at Xilio Therapeutics, Inc., where they focused on in vivo pharmacology, and as a Scientist at Compass Therapeutics LLC, where they studied anti-tumor immunity using mouse tumor models. Hsin-Jung Wu's earlier experience includes working as a Postdoctoral Fellow at the University of Cincinnati College of Medicine, where they researched cell-cell communication within the tumor microenvironment, and as a Graduate Student Research Assistant at Indiana University Bloomington, where they conducted research on tissue regeneration using mesenchymal stem cells. Hsin-Jung also served as an Associate Instructor during their time at Indiana University Bloomington.
Hsin-Jung Wu received a Bachelor's degree in Public Health from National Taiwan University in 2007. From 2009 to 2015, they pursued a Doctor of Philosophy (Ph.D.) in Pharmacology at Indiana University Bloomington.
August, 2022 - present
Research Recruiting Manager at OpenAI
Research Project Director Atlas|aai at The University of Kansas
Director Of Administration And Fiscal Affairs - Office Of The Vice President For Research at University of Alabama at Birmingham
Senior Director, Prospect Research And Management at Northwestern University
Manager, Shared Research Operations at Texas State University
Access the worlds's biggest network of public org charts
Learn more